Literature DB >> 29208371

Integrated semi-targeted metabolomics analysis reveals distinct metabolic dysregulation in pleural effusion caused by tuberculosis and malignancy.

Nanying Che1, Yan Ma2, Huabin Ruan3, Lina Xu3, Xueying Wang3, Xinting Yang4, Xiaohui Liu5.   

Abstract

BACKGROUND: Tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) are the 2 most frequent causes of exudative pleural effusions (PEs). However, the clinical differentiation is challenging.
METHODS: Metabolic signatures in pleural effusion from 156 patients were profiled. An integrated semi-targeted metabolomics platform was incorporated for high throughput metabolite identification and quantitation. In this platform, orbitrap based mass spectrometry with data dependent MS/MS acquisition was applied in the analysis. In-house database containing ~1000MS/MS spectra were established and "MetaInt" was developed for metabolite alignment.
RESULTS: Using this strategy, lower levels of amino acids, citric acid cycle intermediates and free fatty acids accompanied with elevated acyl-carnitines and bile acids were observed, demonstrating increased energy expenditure caused by TPE. Kynurenine pathway from tryptophan was significantly enhanced in TPE. The ratio of tryptophan/kynurenine exhibited decent performance in differentiating TPE from MPE with sensitivity of 92.7% and specificity of 86.1%. After two further independent validations, it turns out that the ratio of tryptophan/kynurenine can be applied confidently as a potential biomarker together with adenosine deaminase (ADA) for clinical diagnosis of TPE.
CONCLUSIONS: Conclusively, the integrated in-house platform for high throughput semi-targeted metabolomics analysis reliably identified great potential of tryptophan/kynurenine ratio as a novel diagnostic biomarker to distinguish pleural effusion caused by tuberculosis and malignancy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; High throughput; Mass spectrometry; Pleural effusion; Semi-targeted metabolomics; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 29208371     DOI: 10.1016/j.cca.2017.12.003

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Selenium Deficiency-Induced Pancreatic Pathology Is Associated with Oxidative Stress and Energy Metabolism Disequilibrium.

Authors:  Shuang Li; Qingyu Zhao; Kai Zhang; Wenjuan Sun; Jing Li; Xiaoqing Guo; Jingdong Yin; Junmin Zhang; Chaohua Tang
Journal:  Biol Trace Elem Res       Date:  2020-04-20       Impact factor: 3.738

Review 2.  Understanding Metabolic Regulation Between Host and Pathogens: New Opportunities for the Development of Improved Therapeutic Strategies Against Mycobacterium tuberculosis Infection.

Authors:  Ji-Hae Park; Dahee Shim; Keu Eun San Kim; Wonsik Lee; Sung Jae Shin
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

3.  Targeted metabolomics analysis of serum and Mycobacterium tuberculosis antigen-stimulated blood cultures of pediatric patients with active and latent tuberculosis.

Authors:  Druszczynska Magdalena; Seweryn Michal; Sieczkowska Marta; Kowalewska-Pietrzak Magdalena; Pankowska Anna; Godkowicz Magdalena; Szewczyk Rafał
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

Review 4.  Bile Acid Detection Techniques and Bile Acid-Related Diseases.

Authors:  Xiang Zhao; Zitian Liu; Fuyun Sun; Lunjin Yao; Guangwei Yang; Kexin Wang
Journal:  Front Physiol       Date:  2022-03-16       Impact factor: 4.566

5.  Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children.

Authors:  Noton K Dutta; Jeffrey A Tornheim; Kiyoshi F Fukutani; Mandar Paradkar; Rafael T Tiburcio; Aarti Kinikar; Chhaya Valvi; Vandana Kulkarni; Neeta Pradhan; Shri Vijay Bala Yogendra Shivakumar; Anju Kagal; Akshay Gupte; Nikhil Gupte; Vidya Mave; Amita Gupta; Bruno B Andrade; Petros C Karakousis
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.